Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Advanced Rare Genitourinary Tumors
NCT03333616Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2017
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in genitourinary cancer, adrenocortical carcinoma (ACC), bladder cancer, Malignant neoplasm of renal pelvis and ureter (UTUC), penile cancer, sponsored by Dana-Farber Cancer Institute. Started Dec 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
genitourinary canceradrenocortical carcinoma (ACC)bladder cancerMalignant neoplasm of renal pelvis and ureter (UTUC)penile cancer
Beyond the preview
Go deeper on NCT03333616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333616.